Blog

Many eager investors have been flocking to psychedelics with the “gold rush” mentality over the past few years. Another industry that has seen this pattern over the past decade is rehab. The burgeoning psychedelic treatment space has a lot of cross-over with addiction treatment and rehabilitation.  In 2020, drug and alcohol addiction treatment brought in $42 billion, and that number is projected to grow 20% by 2025. The amount of money being poured into rehab programs is growing exponentially, but the results of these programs are less than satisfactory. Given the lack of performance by current addiction treatments, the psychedelic…

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed’s management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022. Canaccord Genuity 42nd Annual Growth ConferenceFormat: In-person presentation and scheduled one-on-one investor meetingsDate: Wednesday, August 10, 2022Time: 11:00 a.m. ETLocation: Boston, MAWebcast Link: https://wsw.com/webcast/canaccord76/mnmd/2453508 A replay of the webcast will be available in the “News & Media” section of MindMed’s website for 90 days following the presentation. About MindMed MindMed is a…

Presented by What would it look like to create a profound, lasting transformation in your life? To completely rewire your brain to support growth and flexibility? To open yourself up to new awareness and insights you have never considered? To spark creativity and inspiration you have never imagined? Or to address and heal trauma from the past? All while experiencing only calm and peace? Floresta wants to show you… with the power of ketamine therapy. Join Floresta for an incredible and life-changing, four-day Psychedelic-Assisted Therapy retreat, designed to help you explore non-ordinary states of consciousness and integration in a safe,…

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic sector, announced that its flagship platform, Psychedelic Spotlight, surpassed one million Page Views in the month of July, as well as setting new monthly records for the following KPI’s: Page Views, Impressions, Organic Visits, and Click Thru Rate (CTR). The accomplishment comes after Psychedelic Spotlight first surpassed one million Page Views in the months of May and June. This is the first time the Company achieved this milestone, and the development, combined with its ongoing top ranking on Google under the search category “psychedelic news,” further solidifies management’s claim to Psychedelic Spotlight…

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis and Chronic Cough, at the 9th American Cough Conference in June, 2023. The American Cough Conference is the world’s leading educational meeting for health care professionals involved in the research and management of patients with cough and is held every two years. “I am pleased that Algernon has accepted our invitation to present at the American Cough Conference,” “The…